The largest database of trusted experimental protocols

Quark pft with x9 pneumotach

Manufactured by Cosmed
Sourced in Italy

The Quark PFT with X9 pneumotach is a laboratory equipment product designed for pulmonary function testing. The core function of this device is to measure and analyze respiratory parameters, such as lung volumes and flow rates, in a clinical or research setting. The X9 pneumotach component is responsible for accurately measuring airflow during the testing process.

Automatically generated - may contain errors

Lab products found in correlation

4 protocols using quark pft with x9 pneumotach

1

Comprehensive Pulmonary Function Evaluation

Check if the same lab product or an alternative is used in the 5 most similar protocols
All patients underwent standard pulmonary function testing (PFT) (with a Quark PFT with X9 pneumotach, COSMED srl, Roma, Italy) for forced expiratory volume in one second (FEV1), vital capacity (VC), forced vital capacity (FVC), DLCO and total lung capacity (TLC). DLCO and TLC were determined by the single-breath carbon monoxide technique. The examination was performed on the same day of the visit.
+ Open protocol
+ Expand
2

Standardized Pulmonary Function Testing Protocols

Check if the same lab product or an alternative is used in the 5 most similar protocols
All patients underwent standard pulmonary function testing (PFT) with a Quark PFT with X9 pneumotach (COSMED) for forced expiratory volume in 1 second (FEV1), vital capacity, forced vital capacity (FVC), Dlco, Dlco constant, and total lung capacity. Dlco and total lung capacity were determined by the single-breath co technique. The hemoglobin value was evaluated before PFT to apply the appropriate correction to Dlco.
The spirometer underwent calibration the day the test was performed, and barometric pressure and temperature were simultaneously recorded. A trained technician coached the patient, while a pulmonologist (E. C., E. P., or F. P.) was responsible for test validation and interpretation based on the 2005 the American Thoracic Society and European Respiratory Society statements.12 (link),13 (link) Briefly, the following safety measures were adopted: in a dedicated room, a dedicated spirometer was used to avoid cross-infection of patients not included in this program. The technician (and the pulmonologist, if needed) used full PPE (ie, face mask, N95 respirator, gown, and gloves). To avoid cross-infections between patients included in the program, a mouthpiece with an antimicrobial filter was used and changed for every patient. At the end of each day, the room underwent disinfection.
+ Open protocol
+ Expand
3

Standardized Pulmonary Function Testing

Check if the same lab product or an alternative is used in the 5 most similar protocols
All patients underwent standard pulmonary function tests (PFT) with a Quark PFT with X9 pneumotach (COSMED srl, Rome, Italy) to evaluate forced expiratory volume in 1 second (FEV1), vital capacity, forced vital capacity (FVC), diffusing capacity of the lungs for carbon monoxide (DLCO), DLCO constant, and total lung capacity. DLCO and total lung capacity were determined by the single-breath co technique.
The spirometer was calibrated on the day the test was performed and the barometric pressure and temperature were simultaneously recorded. A trained technician coached the patient, while a pulmonologist was responsible for test validation and interpretation based on the 2005 the American Thoracic Society and European Respiratory Society statements. Appropriate safety measures were adopted (including use of a dedicated spirometer to avoid cross-infection, use of a mouthpiece with a different antimicrobial filter for each patient and use of complete PPE by the staff). At the end of each day, the room underwent disinfection.
+ Open protocol
+ Expand
4

COVID-19 Long-Term Impacts on Lung Function and Hair Loss

Check if the same lab product or an alternative is used in the 5 most similar protocols
Data about patients’ demographic characteristics, ongoing drugs, symptoms at COVID-19 diagnosis and follow-up evaluation, complications during their hospital stay, and their type and number of comorbidities were collected by clinicians involved in the treatment of patients. Among the signs and symptoms investigated, we recorded whether the patients experienced hair loss in the follow-up period. These subjects were invited to answer a short retrospective questionnaire about the nature and persistence of hair loss. The severity of the acute phase of the disease was classified using an eight-category scale, as previously described [47 (link)]. Moreover, all patients underwent standard pulmonary function testing (PFT) with a Quark PFT with X9 pneumotach (COSMED) for assessing the forced expiratory volume in 1 s (FEV1), vital capacity, forced vital capacity (FVC), and diffusion capacity of the lung for carbon monoxide (DLCO), and the total lung capacity was determined by the single-breath CO technique.
+ Open protocol
+ Expand

About PubCompare

Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.

We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.

However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.

Ready to get started?

Sign up for free.
Registration takes 20 seconds.
Available from any computer
No download required

Sign up now

Revolutionizing how scientists
search and build protocols!